Scott B. Ullem - 07 May 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
07 May 2023
Transactions value $
-$415,126
Form type
4
Filing time
09 May 2023, 19:48:43 UTC
Previous filing
04 May 2023
Next filing
11 May 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $0 +6,062 +36% $0 22,972 07 May 2023 Direct F1
transaction EW Common Stock Tax liability -$266,574 -3,004 -13% $88.74 19,968 07 May 2023 Direct
transaction EW Common Stock Tax liability -$148,550 -1,674 -8.4% $88.74 18,294 08 May 2023 Direct
holding EW Common Stock 257,822 07 May 2023 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -6,062 -78% $0 1,663 07 May 2023 Common Stock 6,062 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.